pubmed.ncbi.nlm.nih.gov

Overlapping RNA and DNA binding domains of the wt1 tumor suppressor gene product - PubMed

️Thu Jan 01 1998

Overlapping RNA and DNA binding domains of the wt1 tumor suppressor gene product

N Bardeesy et al. Nucleic Acids Res. 1998.

Abstract

The Wilms' tumour suppressor gene (wt1) is mutated in a subset of patients with Wilms' tumour and has a critical role in urogenital development. wt1 encodes a zinc finger transcription factor which regulates expression of several genes involved in cellular proliferation and differentiation. Although a number of studies have characterized the DNA binding properties of the WT1 protein, recent evidence has suggested that WT1 may also have a role in RNA metabolism. We have used an RNA selection method to identify WT1 binding ligands from a random RNA pool. Three groups of RNA ligands specifically recognized by WT1 were identified. Mutational analysis pinpointed ribonucleotide sequences critical for binding. Analysis of truncated WT1 proteins demonstrated that three of four zinc fingers were necessary for RNA-protein interaction. The naturally occurring WT1 isoforms with insertion of lysine, threonine and serine between zinc fingers three and four were unable to bind the selected RNAs. The selected RNA ligands competed with the cognate WT1 DNA binding site for complex formation with WT1. Our findings suggest potential cellular RNA target sequences for WT1 and provide tools for studying the structural and functional properties of this tumour suppressor protein.

PubMed Disclaimer

Cited by

RNA aptamers and their therapeutic and diagnostic applications.
Germer K, Leonard M, Zhang X. Germer K, et al. Int J Biochem Mol Biol. 2013 Mar 31;4(1):27-40. Print 2013. Int J Biochem Mol Biol. 2013. PMID: 23638319 Free PMC article.
Regulation of gene expression by WT1 in development and tumorigenesis.
Ellisen LW. Ellisen LW. Int J Hematol. 2002 Aug;76(2):110-6. doi: 10.1007/BF02982572. Int J Hematol. 2002. PMID: 12215008 Review.
Ligand-targeted theranostic nanomedicines against cancer.
Yao VJ, D'Angelo S, Butler KS, Theron C, Smith TL, Marchiò S, Gelovani JG, Sidman RL, Dobroff AS, Brinker CJ, Bradbury ARM, Arap W, Pasqualini R. Yao VJ, et al. J Control Release. 2016 Oct 28;240:267-286. doi: 10.1016/j.jconrel.2016.01.002. Epub 2016 Jan 6. J Control Release. 2016. PMID: 26772878 Free PMC article. Review.
The Wilms' tumor 1 (WT1) gene (+KTS isoform) functions with a CTE to enhance translation from an unspliced RNA with a retained intron.
Bor YC, Swartz J, Morrison A, Rekosh D, Ladomery M, Hammarskjöld ML. Bor YC, et al. Genes Dev. 2006 Jun 15;20(12):1597-608. doi: 10.1101/gad.1402306. Epub 2006 May 31. Genes Dev. 2006. PMID: 16738405 Free PMC article.
Whole exome sequencing identified a rare WT1 loss-of-function variant in a non-syndromic POI patient.
Wang Y, Chen Q, Zhang F, Yang X, Shang L, Ren S, Pan Y, Zhou Z, Li G, Fang Y, Jin L, Wu Y, Zhang X. Wang Y, et al. Mol Genet Genomic Med. 2022 Jan;10(1):e1820. doi: 10.1002/mgg3.1820. Epub 2021 Nov 29. Mol Genet Genomic Med. 2022. PMID: 34845858 Free PMC article.

References

1. Oncogene. 1995 Nov 2;11(9):1781-92 - PubMed
1. Mol Cell Biol. 1994 Oct;14(10):6570-83 - PubMed
1. Proc Natl Acad Sci U S A. 1995 Dec 19;92(26):11960-4 - PubMed
1. Nat Genet. 1996 Mar;12(3):329-31 - PubMed
1. RNA. 1996 Jan;2(1):38-50 - PubMed

Overlapping RNA and DNA binding domains of the wt1 tumor suppressor gene product - PubMed